Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Efficacy of laparoscopic pyloroplasty for the treatment of gastroparesis
The LEADER trial provided landmark evidence that liraglutide reduces cardiovascular death and major adverse cardiovascular events in patients with type 2 diabetes
Written By: Abhinay Wadekar, BPharm Reviewed By: Pharmacally Editorial Team Innovent Biologics, Inc., announced landmark results from its fourth Phase 3 clinical trial, DREAMS-3, investigating mazdutide a dual GLP-1 and glucagon (GCG) receptor agonist in Chinese patients diagnosed with type 2 diabetes (T2D) and obesity
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit
